Biased Ligands. Better Drugs.

Press Releases

7/1/14 - Trevena Appoints Julie H. McHugh and Barbara Yanni to the Board of Directors

Trevena, Inc. (NASDAQ: TRVN), today announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined Trevena’s Board of Directors. Read More

6/24/14 - Results of Phase 1b Clinical Trial Comparing Trevena’s TRV130 to Morphine Published in the Journal Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the publication of its Phase 1b data for TRV130 in the journal Pain. Read More

6/23/14 - Trevena Announces Positive Phase 1 Results for TRV734 for Acute and Chronic Pain
Trevena, Inc. (NASDAQ: TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids. The study tested single ascending doses and the relative bioavailability of oral TRV734 in healthy subjects, and demonstrated that TRV734 is pharmacologically active at a range of safe and well-tolerated doses. Read More

5/27/14 - Trevena CEO to Present at the Jefferies 2014 Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 11:00 a.m. EDT in New York City. Read More

5/19/14 - Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting
Trevena, Inc. (NASDAQ: TRVN), today announced that it presented the trial design rationale for its ongoing Phase 2b BLAST-AHF Study of TRV027 in acute heart failure (AHF) at the European Society of Cardiology Heart Failure (ESC-HF) 2014 Meeting, which is taking place May 17 – 20, 2014 in Athens, Greece. Read More

5/15/14 - Trevena Appoints John M. Limongelli as General Counsel
Trevena, Inc. (NASDAQ: TRVN), today announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately. Read More

5/9/14 - Trevena Reports First Quarter 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the quarter ended March 31, 2014. Read More

5/2/14 - Trevena to Host Conference Call on May 9th to Discuss First Quarter 2014 Financial Results and Recent Highlights
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Friday, May 9, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2014. Read More

5/2/14 - Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting
Trevena, Inc. (NASDAQ: TRVN), announced that data from the Company’s Phase 1b trial of TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, are being presented today in a poster session at the American Pain Society Annual Meeting in Tampa, Florida. Read More

5/1/14 - Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the initiation of a Phase 2a/b clinical trial with TRV130, a small molecule G protein biased ligand at the mu opioid receptor, which Trevena is developing as a first-line intravenous treatment for patients experiencing moderate to severe acute pain where intravenous administration is preferred. Read More

4/1/14 - Trevena CEO to Present at the 13th Annual Needham Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 2:20 p.m. ET in New York City. Read More

4/1/14 - Trevena Appoints Robert Prachar as SVP, Commercial and Corporate Strategy
Trevena, Inc. (NASDAQ: TRVN), today announced the appointment of Robert Prachar to the newly created position of Senior Vice President, Commercial and Corporate Strategy, effective immediately. Mr. Prachar, who has served as a full-time consultant for the Company since August 2013, brings over 20 years of commercial leadership experience in the life sciences industry. Read More

3/20/14 - Trevena Reports Full Year 2013 Financial Results
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the year ended December 31, 2013. Read More

3/13/14 - Trevena to Host Conference Call on March 20th to Discuss Full Year 2013 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2013. Read More

3/7/14 - Trevena Announces Partial Exercise of Underwriters’ Overallotment Option
Trevena, Inc. (NASDAQ: TRVN), today announced that the underwriters for its initial public offering of common stock have partially exercised their over-allotment option and purchased an additional 270,449 shares. Read More

3/5/14 - Trevena CEO to Present at the Barclays Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014 at 10:45 a.m. ET in Miami, FL. Read More

2/5/14 - Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain. Read More

2/5/14 - Trevena Announces Closing of Initial Public Offering
Trevena, Inc. (NASDAQ: TRVN), today announced the closing of its initial public offering of 9,250,000 shares of common stock at an initial public offering price of $7.00 per share. Read More

1/31/14 - Trevena Increases Offering
Trevena, Inc., today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share. Trevena previously announced that the number of shares in the offering was 8,500,000. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. Read More

1/30/14 - Trevena Announces Pricing of its Initial Public Offering
Trevena, Inc., today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a price of $7.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. Read More

News Archive

Copyright © Trevena, Inc.